The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.本文所揭示的內容係針對藉由皮下地投予奧氮平或其醫藥上可接受的鹽之持續釋放劑型來治療精神分裂症或雙極性情感疾患的方法。本文亦描述皮下地投予奧氮平或其醫藥上可接受的鹽的方法。